Vyndaqel and Paraesthesia - a phase IV clinical study of FDA data

Summary:

Paraesthesia is reported as a side effect among people who take Vyndaqel (tafamidis meglumine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Eliquis, and have Cardiac amyloidosis.

The phase IV clinical study analyzes which people have Paraesthesia when taking Vyndaqel. It is created by eHealthMe based on reports of 3,783 people who have side effects when taking Vyndaqel from the FDA, and is updated regularly.

What is Vyndaqel?

Vyndaqel has active ingredients of tafamidis meglumine. eHealthMe is studying from 3,783 Vyndaqel users. Check the latest studies of Vyndaqel.

What is Paraesthesia?

Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect) is found to be associated with 2,689 drugs and 3,120 conditions by eHealthMe. Check the latest studies of Paraesthesia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

3,783 people reported to have side effects when taking Vyndaqel.
Among them, 26 people (0.69%) have Paraesthesia.

Among these 26 people:

How long have people been on Vyndaqel when they have Paraesthesia? *

What is the gender of people who have Paraesthesia when taking Vyndaqel? *

female: 24 %
male: 76 %

What is the age of people who have Paraesthesia when taking Vyndaqel? *

What are other drugs people take besides Vyndaqel? *

What are other side effects people have besides Paraesthesia? *

Hypoaesthesia (reduced sense of touch or sensation): 13 people, 50.00%
Weakness: 11 people, 42.31%
Gait Disturbance: 8 people, 30.77%
Diarrhea: 6 people, 23.08%
Neuropathy Peripheral (surface nerve damage): 6 people, 23.08%
Fatigue (feeling of tiredness): 5 people, 19.23%
Abdominal Distension: 5 people, 19.23%
Dizziness: 5 people, 19.23%
Dyspnea (difficult or laboured breathing): 5 people, 19.23%
Balance Disorder: 4 people, 15.38%

What are the existing conditions these people have? *

Cardiac Amyloidosis (protein deposition in heart): 14 people, 53.85%
Amyloidosis (a tumour within which amyloid is produced): 11 people, 42.31%
Blood Pressure Abnormal: 4 people, 15.38%
Hereditary Neuropathic Amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves): 3 people, 11.54%
Hypokalemia (low potassium): 2 people, 7.69%
High Blood Cholesterol: 2 people, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 7.69%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 7.69%
Enlarged Prostate: 2 people, 7.69%
Cardiac Disorder: 2 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Vyndaqel and have Paraesthesia?

- Check whether Paraesthesia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyndaqel:

Vyndaqel (3,783 reports)

Paraesthesia treatments and more:

Paraesthesia (184,215 reports)

Browse all side effects of Vyndaqel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paraesthesia:

Paraesthesia (2,689 drugs)

Browse all the conditions that are associated with Paraesthesia:

Paraesthesia (3,120 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tafamidis meglumine (the active ingredients of Vyndaqel) and Vyndaqel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.